免疫检查点抑制剂（ICIs）联合血管生成抑制剂已被用于治疗晚期肺癌。目前认为其相关的治疗相关不良事件（trAEs）是可接受的，然而尚未得出结论。我们旨在总结ICIs联合血管生成抑制剂治疗晚期肺癌患者所产生的trAEs。筛选符合以下标准的研究：在干预或观察性研究中接受ICIs联合血管生成抑制剂（包括化疗或不包括化疗）治疗的晚期肺癌患者。结果包括trAEs或免疫相关不良事件（irAEs）的类型和数量、与治疗相关的停药和死亡情况、总生存期（OS）和无进展生存期（PFS）。CRD42022337656号。研究纳入了32个试验，涉及2313名患者，共出现了7768个任何等级的trAEs和1078个≥3级的trAEs。任何等级的trAEs的综合发生率为87.33%（95%置信区间[CI]：79.49-93.65；I2 = 94.04%），≥3级trAEs的综合发生率为38.63%（95% CI：28.28-49.50；I2 = 95.61%）。共涉及了132种任何等级trAEs，涉及18个系统，和99种≥3级trAEs涉及16个系统。对于所有trAEs，我们观察到治疗线路、试验设计、治疗联合和血管生成抑制剂的类型存在显著差异（所有P < 0.05）。trAEs的发生率随药物剂量和频率增加而增加。综合发生率的停药和死亡率分别为10.64%和0.81%。近647名患者经历了irAEs，包括636个任何等级的irAEs和154个≥3级的irAEs。总体上，ICIs联合血管生成抑制剂引发的trAEs的发生率普遍可接受。这些trAEs具有广泛的谱，几乎涵盖了所有不良事件的范围。≥3级trAEs与血管生成抑制剂的关联性更高于任何等级的trAEs。然而，与治疗相关的死亡仍然令人担忧。版权所有 © 2023。由Elsevier B.V.出版。

Immune checkpoint inhibitors (ICIs) with angiogenesis inhibitors have been used to treat advanced lung cancer. Their associated treatment-related adverse events (trAEs) are currently considered acceptable; however, no conclusion has been reached. We aimed to summarize the trAEs caused by ICIs combined with angiogenesis inhibitors in patients with advanced lung cancer.Pulled studies met the following criteria: patients with advanced lung cancer who received treatment involving ICIs combined with angiogenesis inhibitors (with or without chemotherapy) in interventional or observational studies. Results included the type and number of trAEs or immune-related adverse events (irAEs), treatment-associated discontinuation and mortality, overall survival (OS), and progression-free survival (PFS).CRD42022337656.The study enrolled 32 trials involving 2313 patients who had 7768 any-grade trAEs and 1078 grade ≥3 trAEs. The pooled incidences were 87.33% (95% confidence interval [CI]: 79.49-93.65; I2 = 94.04%) for any-grade trAEs, and 38.63% (95% CI: 28.28-49.50; I2 = 95.61%) for grade ≥3 trAEs. There were 132 kinds of any-grade trAEs involving 18 systems, and 99 kinds of grade ≥3 trAEs involving 16 systems. For all trAEs, we observed significant differences in the line of therapy, trial design, therapy combination, and types of angiogenesis inhibitors (all P < 0.05). The rate of trAEs increased with dosage and frequency of medication. Pooled incidences of discontinuation and mortality were 10.64% and 0.81%, respectively. Nearly 647 patients experienced irAEs, including 636 any-grade irAEs and 154 grade ≥3 irAEs.Overall, the incidence of trAEs caused by ICIs combined with angiogenesis inhibitors is generally acceptable. These trAEs have a wide spectrum nearly covering the full range of adverse events. Grade ≥3 trAEs are more closely associated with angiogenesis inhibitors than any grade. However, treatment-associated mortality remains concerning.Copyright © 2023. Published by Elsevier B.V.